MX2022009165A - Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal. - Google Patents
Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal.Info
- Publication number
- MX2022009165A MX2022009165A MX2022009165A MX2022009165A MX2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney
- integrin
- kidney disease
- antibodies
- tissue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan métodos y composiciones para tratar una enfermedad renal, tal como enfermedad renal crónica (CKD), en los que los métodos y composiciones comprenden anticuerpos o un fragmento de unión al antígeno de estos que se unen de manera específica y selectiva a la integrina avß8 humana, de la que se descubrió, como se describe, que presenta una expresión muy elevada en células y tejido renales y, en particular, tejido renal enfermo o fibrótico. Los anticuerpos contra la integrina avß8 divulgados se unen a la integrina avß8 humana en el riñón y bloquean la activación de TGF-ß a partir de su forma latente en el tejido renal. Los anticuerpos contra avß8 en los métodos divulgados reducen, atenúan o anulan la fibrosis renal, que está asociada con la actividad de la integrina avß8 y TGF-ß en el tejido renal. Los anticuerpos y métodos divulgados tratan de manera eficaz la enfermedad renal, en particular, la fibrosis asociada con la enfermedad renal, tal como CKD, en individuos que lo necesiten.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966258P | 2020-01-27 | 2020-01-27 | |
PCT/EP2021/051753 WO2021151889A1 (en) | 2020-01-27 | 2021-01-26 | ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009165A true MX2022009165A (es) | 2022-08-16 |
Family
ID=74561850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009165A MX2022009165A (es) | 2020-01-27 | 2021-01-26 | Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230112035A1 (es) |
EP (1) | EP4096785A1 (es) |
JP (1) | JP2023511686A (es) |
KR (1) | KR20220132567A (es) |
CN (1) | CN115151305A (es) |
AR (1) | AR121193A1 (es) |
AU (1) | AU2021213403A1 (es) |
BR (1) | BR112022014633A2 (es) |
CA (1) | CA3167390A1 (es) |
CL (1) | CL2022001999A1 (es) |
CO (1) | CO2022011661A2 (es) |
CR (1) | CR20220392A (es) |
EC (1) | ECSP22066085A (es) |
IL (1) | IL294814A (es) |
MX (1) | MX2022009165A (es) |
TW (1) | TW202140554A (es) |
WO (1) | WO2021151889A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP4219560A3 (en) * | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
EP2744823B1 (en) | 2011-08-17 | 2017-08-02 | The Regents of the University of California | Antibodies that bind integrin alpha-v beta-8 |
JP2017522289A (ja) | 2014-06-17 | 2017-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善されたα−Vβ−8抗体 |
WO2018227018A1 (en) * | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
-
2021
- 2021-01-13 TW TW110101209A patent/TW202140554A/zh unknown
- 2021-01-26 AU AU2021213403A patent/AU2021213403A1/en active Pending
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 JP JP2022545136A patent/JP2023511686A/ja active Pending
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en active Application Filing
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Search and Examination
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202140554A (zh) | 2021-11-01 |
CR20220392A (es) | 2022-09-07 |
ECSP22066085A (es) | 2022-09-30 |
CL2022001999A1 (es) | 2023-01-27 |
CO2022011661A2 (es) | 2022-08-30 |
KR20220132567A (ko) | 2022-09-30 |
CN115151305A (zh) | 2022-10-04 |
IL294814A (en) | 2022-09-01 |
JP2023511686A (ja) | 2023-03-22 |
EP4096785A1 (en) | 2022-12-07 |
BR112022014633A2 (pt) | 2022-09-13 |
CA3167390A1 (en) | 2021-08-05 |
AU2021213403A1 (en) | 2022-09-15 |
AR121193A1 (es) | 2022-04-27 |
WO2021151889A1 (en) | 2021-08-05 |
US20230112035A1 (en) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009165A (es) | Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal. | |
PH12020551865A1 (en) | Anti-msr1 antibodies and methods of use thereof | |
NZ599875A (en) | Human il-23 antigen binding proteins | |
NZ592054A (en) | Dengue virus neutralizing antibodies and uses thereof | |
EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
WO2007092939A3 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
WO2007042309A3 (en) | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 | |
TW200745162A (en) | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 | |
WO2008137901A3 (en) | Methods for treating and preventing gi syndrome and graft versus host disease | |
MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
TR201907261T4 (tr) | DKK-1 antikorları. | |
ATE500276T1 (de) | Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung | |
EA201491452A1 (ru) | Антитела к asic1 и их применение | |
MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
ZA202205927B (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
MX2022014995A (es) | Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april. | |
MX2019013137A (es) | Metodos y composiciones para tratar enfermedades oculares alergicas. | |
MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
MX2018011025A (es) | Metodos para tratar o prevenir la enfermedad del injerto contra huésped. | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения |